Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) EBT (2016 - 2025)

Wave Life Sciences' EBT history spans 11 years, with the latest figure at -$53.2 million for Q4 2025.

  • For Q4 2025, EBT fell 281.79% year-over-year to -$53.2 million; the TTM value through Dec 2025 reached -$204.4 million, down 110.68%, while the annual FY2025 figure was -$204.4 million, 110.68% down from the prior year.
  • EBT reached -$53.2 million in Q4 2025 per WVE's latest filing, up from -$53.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $29.3 million in Q4 2024 to a low of -$61.8 million in Q3 2024.
  • Average EBT over 5 years is -$32.2 million, with a median of -$38.3 million recorded in 2021.
  • The largest YoY upside for EBT was 279.95% in 2024 against a maximum downside of 1039.62% in 2024.
  • A 5-year view of EBT shows it stood at -$35.0 million in 2021, then decreased by 22.98% to -$43.0 million in 2022, then soared by 62.22% to -$16.3 million in 2023, then soared by 279.95% to $29.3 million in 2024, then plummeted by 281.79% to -$53.2 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's EBT are -$53.2 million (Q4 2025), -$53.9 million (Q3 2025), and -$50.5 million (Q2 2025).